Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

Mortality was higher in the RSV cohort, with a 10.1% death rate, compared to 5.5% for flu. RSV infection showed a 52% higher ...

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

When you catch a cold or the flu, a sore throat is often a symptom, making swallowing and talking uncomfortable. With ...

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...